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Liver cirrhosis is frequently associated with diabetes mel-
litus (DM), and this metabolic complication is also fre-
quent after orthotopic liver transplantation (OLT). The
aim of our study is to investigate which factors are associ-
ated with DM before and after OLT and their impact on
post-OLT evolution. We evaluated the prevalence of DM
among 115 liver transplant candidates with cirrhosis and
assessed their evolution after OLT (median follow-up, 41
months). Sixteen candidates had DM requiring pharma-
cological therapy (group A), 45 candidates had DM con-
trolled with diet (group B), and 54 candidates did not
have DM (group C). One-year and 3-year actuarial sur-
vival rates were 100% and 100% for group A, 91% and
85% for group B, and 77% and 74% for group C, respec-
tively (P < .03). Post-OLT DM was more frequent in
group A. The incidence of other metabolic complications,
major infections, rejection, and arterial hypertension; the
need for hospitalization; and renal and graft function of
patients in groups A, B, and C were similar. The only risk
factor for DM 1 year after OLT on multivariate analysis
was pre-OLT DM requiring pharmacological treatment.
The incidence of complications, need for hospitalization,
and renal and graft function 1 year after OLT for patients
with post-OLT DM were similar to those of patients with-
out post-OLT DM. In conclusion, patients with cirrhosis
who have DM have a greater risk for post-OLT DM, but
their midterm survival is not worse than the survival of
those without DM. (Liver Transpl 2001;7:226-233.)
Liver cirrhosis is frequently associated with impairedglucose metabolism.1-3 Insulin resistance has been
found in most patients with cirrhosis.4-6 It seems to be
caused mainly by a deficiency in insulin-stimulated gly-
cogen synthesis in the muscle.4 This insulin resistance
increases the demand for pancreatic insulin secretion
and may lead to overt diabetes mellitus (DM),7 found
in 10% to 30% of the patients with cirrhosis.
Glucose intolerance and insulin resistance of pa-
tients with cirrhosis are reversed after orthotopic liver
transplantation (OLT),8 but the use of such immuno-
suppressive drugs as cyclosporine, tacrolimus, or pred-
nisone can alter glucose metabolism either by direct
effect on pancreatic b-cells or by contributing to insulin
resistance.9-11 Thus, the global effect of OLT on glucose
metabolism may be both prodiabetogenic and antidia-
betogenic.
Some studies have reported the evolution of trans-
plant recipients with DM after OLT.12-17 In 1 study,13
liver transplant recipients with DM had a lower survival
rate than those without DM. Conversely, other studies
did not show a difference between patients with and
without DM.12,14-17 In these studies, DM had been
diagnosed according to serum fasting glucose levels,
probably underestimating the incidence of liver cirrho-
sis–related DM.
The aim of this study is to investigate the prevalence
of pre-OLT DM in end-stage liver cirrhosis and assess
the evolution of patients with DM after OLT. In addi-
tion, factors predisposing to post-OLT DM were stud-
ied.
Patients and Methods
Study Design and Population
From February 1990 to October 1998, a total of 115 adult
patients with liver cirrhosis undergoing OLT at a single insti-
tution were studied before OLT by means of an oral glucose
tolerance test (OGTT) to rule out DM, unless they had a
previous reported diagnosis of DM. According to the 1997
recommendations of the American Diabetes Association,18
DM was diagnosed if fasting serum glucose levels were greater
than 126 mg/dL or serum glucose concentrations were greater
than 200 mg/dL 120 minutes after an OGTT using 75 g of
anhydrous glucose. Impaired glucose tolerance was diagnosed
when serum glucose levels were between 140 and 200 mg/dL
120 minutes after OGTT.
After DM was diagnosed, a diet avoiding simple sugars
and limiting carbohydrate to 4 g/kg/d and regular exercise
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were recommended. If these measures were not sufficient to
get good metabolic control, drug therapy (oral hypoglycemic
agents or insulin) was initiated. Patients were divided into 3
groups: patients with DM requiring treatment other than diet
and exercise (insulin or oral hypoglycemic agents) for control
of DM (group A): patients with DM without need of phar-
macological treatment (group B), and patients without DM
(group C). None of the liver transplant recipients with DM
had clinical, electrocardiographic, or echocardiographic find-
ings suggestive of ischemic cardiac disease, major cerebrovas-
cular disease (not including asymptomatic lacunar infarcts),
advanced renal insufficiency, disabling peripheral neuropa-
thy, or vasculopathy.
Post-OLT Patient Management
Immunosuppression consisted of a triple-drug regimen in-
cluding cyclosporine or tacrolimus, azathioprine, and ste-
roids. Before 1996, cyclosporine was administered intrave-
nously (2 mg/kg twice daily) in the immediate postoperative
period and was switched to the oral route. From 1996, ther-
apy with oral cyclosporine microemulsion (5 mg/kg twice
daily) was started in the immediate postoperative period. Pa-
tients administered tacrolimus were treated initially with
0.05 mg/kg orally twice daily. Cyclosporine and tacrolimus
doses were adjusted according to blood trough levels. Patients
on cyclosporine therapy were administered 1,000 mg of in-
travenous methylprednisolone intraoperatively, followed by a
tapering schedule of 200 to 20 mg/d in the first 6 postopera-
tive days. Patients treated with tacrolimus were administered
5 mg/kg of methylprednisolone intraoperatively and in the
first postoperative day, reduced to 20 mg/d on postoperative
day 2. Prednisone dosage was slowly reduced, and its with-
drawal was attempted 12 to 24 months after OLT from 1990
to 1996 and 6 to 12 months after OLT from 1997 to 1998.
Azathioprine was administered at a dose of 1 to 2 mg/kg/d
and adjusted according to hematologic tolerance. After ste-
roid withdrawal, azathioprine dosage was slowly reduced until
it was discontinued. Mild episodes of graft rejection were
treated with an increase in cyclosporine or tacrolimus dose.
Those patients who did not respond to this change in therapy
or those with moderate or severe rejection were treated with a
short course of high-dose steroid therapy (methylpredniso-
lone, 1,000 mg/d intravenously for 3 days), followed by a
6-day tapering dosage (methylprednisolone from 200 to 20
mg/d intravenously).
All patients were administered systemic perioperative an-
tibiotic prophylaxis with amoxicillin/clavulanate for 2 days
and oral administration of norfloxacin, cloxacillin, and nysta-
tin for 4 to 6 days.
After discharge, patients were regularly followed up by
staff members of the liver transplant unit every week for the
first month, every 15 days for the next 3 months, and then
every month for the first year. If there were no complications,
subsequent follow-up was every 3 months thereafter.
The OGTT was not repeated after OLT; therefore, post-
OLT DM was defined as the need for pharmacological treat-
ment (insulin or oral antidiabetic agents) to maintain normal
glucose levels before and after meals and a glycosylated hemo-
globin level less than 6.2%. Hypercholesterolemia was diag-
nosed if fasting serum cholesterol levels were greater than
250 mg/dL in the absence of lipid-reducing therapy. Hyper-
triglyceridemia was defined as a fasting serum triglyceride
level greater than 170 mg/dL. Obesity was defined as a body
mass index (BMI) greater than 30 kg/m2 and overweight as a
BMI between 27 and 30 kg/m2. Arterial hypertension was de-
fined as a diastolic blood pressure greater than 90 mm Hg
and/or a systolic blood pressure greater than 140 mm Hg.
Major infection was defined as a positive culture from blood
or deep tissue associated with the presence of sepsis syndrome.
Data Collection
All patients were followed up until March 1999. Medical
records were retrospectively analyzed for each patient in the
3 groups. The possible relationship between DM and several
pre-OLT variables was analyzed. These variables were age,
sex, blood group, BMI, cause of liver cirrhosis, association
with hepatocellular carcinoma, standard renal and liver func-
tion tests, Child-Pugh status, antidiabetic treatment, HLA-
DR3 and -DR4 antigens, arterial hypertension, hypertriglyc-
eridemia, and hypercholesterolemia.
To assess the possible influence of DM on post-OLT
outcome, survival was compared among groups A, B, and C.
The incidence of DM, obesity, hypercholesterolemia, hyper-
triglyceridemia, and arterial hypertension at 3 months and
1, 2, and 3 years in each group were recorded. The incidence
of major infections and rejection episodes during the first year
post-OLT in the 3 groups was compared. In addition, the
length of hospitalization until intensive care unit and hospital
discharge and in the first post-OLT year were compared
among the 3 groups. Standard hepatic and renal function test
results were also studied during the 3 years of follow-up.
To assess which factors could predispose to post-OLT
DM, patients with and without post-OLT DM 1 year after
OLT were compared. Pre-OLT variables analyzed were age,
sex, blood group, HLA-DR3 and -DR4, incidence of over-
weight or obesity, Child-Pugh status, cause of liver cirrhosis,
presence of hepatocellular carcinoma, hypercholesterolemia,
arterial hypertension, and standard renal and liver function
test results. Post-OLT variables analyzed were daily and cu-
mulative steroid doses, immunosuppression with cyclospor-
ine or tacrolimus, cyclosporine levels, and incidence of rejec-
tion episodes in the first year post-OLT. The possible
influence of tacrolimus levels on the incidence of post-OLT
DM was not studied because of the low number of patients
administered tacrolimus in this series.
The possible influence of post-OLT DM on the evolution
of the patients was assessed by comparing the incidence of
rejection and major infections during the first year post-OLT;
arterial hypertension, hypertriglyceridemia, and hypercholes-
terolemia at the end of the first year post-OLT; serum levels of
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albumin and creatinine; prothrombin ratio; and days of hos-
pitalization required in the intensive care unit, before hospital
discharge, and in the first year.
Statistical Analysis
Statistical analyses were performed using SPSS for Windows
release 9.0.1 (SPSS Inc, Chicago IL). Comparisons of 2 series
of numerical variables were performed with the Mann-Whit-
ney U test. When more than 2 series of continuous variables
were compared, the Kruskal-Wallis test was used, and if P ,
.05, comparisons between groups were performed with the
Mann-Whitney U test and Bonferroni adjustment was finally
applied. Categorical data were compared by Chi-squared test
using Fisher’s correction if indicated.
For analysis of predisposing factors for the development of
post-OLT DM, those variables showing P less than .20 were
included in a multivariate logistic regression model to deter-
mine which factors were independently associated with this
complication. The goodness of fit of the model was assessed
with the Hosmer-Lemeshow test.
Actuarial patient and graft survival rates were estimated by
means of the Kaplan-Meier method and compared by means
of the log-rank test.
Significance was established at P , .05. Continuous vari-
ables are expressed as mean 6 SEM.
Results
Patient Characteristics
Before OLT, 25 patients (22%) had a normal OGTT
result, 29 patients (25%) had impaired glucose toler-
ance, and 61 patients had DM. In only 19 of 61 patients
had DM been diagnosed before referral for OLT. Phar-
macological treatment was required in 16 of 61 patients
with diabetes (26%; group A). Ten of these patients
required insulin (34.10 6 4.34 UI/d); none had DM
type 1 or signs of chronic pancreatitis. Group B con-
sisted of 45 patients (39%) with DM who required only
diet and physical exercise, and group C consisted of
54 patients (47%) without DM.
Pre-OLT demographic, clinical, and laboratory data
from these 3 groups of patients are listed in Table 1. As
expected, fasting serum glucose levels were significantly
greater in patients in group A than in patients in groups
Table 1. Pre-OLT Demographic, Clinical, and Laboratory Data From 115 Liver Transplant Recipients
Group A (n 5 16) Group B (n 5 45) Group C (n 5 54) P
Age (yr) 54.9 6 2.0 56.0 6 1.2 54.1 6 1.3 NS
Sex .004
Men 16 (100) 30 (67) 39 (72)
Women 0 (0) 15 (33) 15 (28)
BMI NS
Normal 8 (50) 29 (64) 30 (55)
Overweight 6 (37) 9 (20) 16 (30)
Obese 2 (13) 7 (16) 8 (15)
Etiology of liver cirrhosis NS
Alcoholic liver disease 10 (62) 12 (27) 22 (41)
Hepatitis C virus 4 (25) 17 (38) 18 (33)
Other 2 (13) 16 (35) 14 (26)
Child-Pugh stage NS
A 3 (19) 5 (11) 8 (15)
B 7 (44) 27 (60) 25 (46)
C 6 (37) 13 (29) 21 (39)
HCC 6 (37) 14 (31) 13 (24) NS
Arterial hypertension 1 (6) 4 (9) 4 (7) NS
Hypercholesterolemia 1 (6) 1 (2) 5 (9) NS
Hypertriglyceridemia 1 (6) 0 (0) 1 (2) NS
Glucose (mg/dL) 137.8 6 12.1 95.1 6 3.3 82.1 6 1.5 ,.001*
Albumin (g/dL) 2.92 6 0.14 2.96 6 0.09 2.90 6 0.07 NS
Prothrombin rate (%) 62 6 3 59 6 2 64 6 3 NS
NOTE. Group A, DM with pharmacological treatment; group B, DM without pharmacological treatment; group C, no DM. Values
expressed as mean 6 SEM or number (percent).
Abbreviations: HCC, hepatocellular carcinoma; NS, not significant.
* Comparisons between all groups (A v B, A v C, B v C), P , .005.
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B and C. There was a significant difference among
groups: all patients in group A were men. The rest of the
variables studied were not significantly different among
groups.
Survival
Patients were followed up for a median of 41 months
(range, 4 to 99 months). At the end of follow-up, 21 pa-
tients had died after OLT (0 patients, group A; 6 pa-
tients, group B; 15 patients, group C). Actuarial sur-
vival rates 1, 3, and 5 years after OLT were 86%, 82%,
and 80% for the whole series; 100%, 100%, and 100%
in group A; 91%, 85%, and 85% in group B; and 77%,
74%, and 71% in group C. Actuarial survival curves are
shown in Figure 1. As noted, the difference in survival
reached statistical significance.
Evolution After OLT
As listed in Table 2, there were no significant differ-
ences among the 3 groups in the incidence of acute
rejection or major infections or the mean number of
hospitalization days required in the intensive care unit,
before post-OLT discharge, or in the first post-OLT
year. Serum albumin and creatinine levels and pro-
thrombin activity were similar among the 3 groups, as
were mean cumulative and daily doses of prednisone.
Table 3 lists the incidence of metabolic complica-
tions in the 3 groups of patients. There were no differ-
ences in the incidence of post-OLT arterial hyperten-
sion, hypercholesterolemia, hypertriglyceridemia, or
overweight or obesity among the 3 groups. The inci-
dence of post-OLT DM 3 months and 1, 2, and 3 years
after OLT was significantly greater in group A than in
groups B and C. The incidence of DM in group B was
greater than that in group C 3 months and 1 year after
OLT, but this difference disappeared by 2 years.
Prevalence and Risk Factors for Post-OLT DM
Ninety-two patients were followed up for more than
1 year after OLT. Twenty-four of these patients had
DM at that time; 22 patients (24%) required insulin
therapy (25.41 6 12.15 UI/d) and 2 patients required
oral antidiabetic therapy to maintain good metabolic
control. Among the variables investigated, history of
pre-OLT DM and incidence of hepatocellular carci-
noma showed P less than .2 on univariate analysis (Ta-
ble 4). On multivariate analysis, only pre-OLT DM
requiring treatment was predictive of post-OLT DM.
Taking group C as the reference stratum, the odds
ratios for DM 1 year after OLT were 3.72 (95% confi-
dence interval, 0.92 to 15.08; P 5 .066) for group B
and 72 (95% confidence interval, 11 to 490; P ,
.0001) for group A. P for Hosmer-Lemeshow test for
goodness of fit was .63.
Consequences of Post-OLT DM
Post-OLT evolutions of patients who did or did not
have DM 1 year after OLT were compared (Table 5).
Both groups were similar in the incidence of acute re-
jection, major infections, overweight or obesity, arterial
hypertension, hypertriglyceridemia, and hypercholes-
terolemia. Days of hospitalization in the intensive care
unit, global hospitalization before discharge, and cu-
mulative 1-year hospitalization were also similar. Creat-
inine and albumin levels and prothrombin activity were
also similar in both groups.
Discussion
Glucose intolerance is a very frequent finding in pa-
tients with end-stage liver cirrhosis. This is mainly
caused by insulin resistance and leads to overt DM in
10% to 30% of patients. In this report, we found a
prevalence of DM greater than 50% in liver transplant
candidates with liver cirrhosis in contrast to its lower
incidence in other series.12-17 A factor that may con-
tribute to this difference is the low proportion of
patients with cholestatic liver disease in our series
compared with others. Zein et al16 found a lower
prevalence of DM in patients with chronic cholesta-
sis than in those with liver cirrhosis caused by hepa-
Figure 1. Actuarial survival after OLT in patients with
pre-OLT DM requiring (group A) or not requiring (group
B) pharmacological treatment and in patients without
DM (group C).
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titis C or alcohol. In our series, 0 of the 7 patients
with chronic cholestasis had DM (and only 1 patient
had impaired glucose tolerance) compared with 22 of
44 patients with alcoholic liver disease and 21 of 39
patients with cirrhosis caused by hepatitis C. This dif-
ferent prevalence is highly significant, but its value is
limited because of the low number of patients with
chronic cholestasis.
The most important reason for this difference be-
tween our study and others is the different criteria used
for the diagnosis of DM. Previous studies had defined
DM as fasting plasma glucose levels greater than
140 mg/dL. In our study, according to the proposal of
the Expert Committee on the Diagnosis and Classifica-
tion of Diabetes Mellitus,18 the diagnosis of DM was
established for fasting plasma glucose levels greater
than 126 mg/dL or plasma glucose levels greater than
200 mg/dL after an OGTT, confirming these results in
a second determination on a separate day. Most diag-
noses of DM were based on the OGTT. Only 7 of
61 patients (11%) with DM had fasting plasma glucose
levels greater than 140 mg/dL. Even if the threshold for
the diagnosis of DM is decreased to 126 mg/dL, only
12 of 61 patients (20%) are correctly diagnosed with
DM. Using the criteria used in other reports, the prev-
alence of DM in our liver transplant recipients was the
same as that in other series.
When we studied which factors are related to liver
cirrhosis–associated DM, the only difference was the
greater prevalence of DM requiring pharmacological
treatment in men. We did not find a difference among
groups with respect to age, blood group, prevalence of
HLA-DR3 or -DR4 antigens, incidence of overweight
or obesity, cause of liver disease (excluding chronic cho-
Table 2. Comparison of Post-OLT Data of Patients
3 Months 1 Year 2 Years 3 Years
Group A
No. of patients 16 14 11 7
Creatinine (mg/dL) 1.14 6 0.09 1.39 6 0.14 1.53 6 0.16 1.31 6 0.07
Cumulative prednisone dose (mg) 4,285 6 481 7,417 6 816 10,134 6 1,083 13,237 6 2,254
Current prednisone dose (mg/d) 16.40 6 1.51 6.43 6 1.25 5.23 6 1.14 5.00 6 2.11
Cyclosporine level (ng/mL) 224 6 27 183 6 19 146 6 33 120 6 28
Rejection episodes 4/16 (31)
Major infections 3/16 (19)
Days in intensive care unit 5.31 6 0.39
In-hospital days 18.63 6 9.62 34.36 6 3.9
Group B
No. of patients 44 38 29 23
Creatinine (mg/dL) 1.12 6 0.04 1.15 6 0.05 1.29 6 0.06 1.30 6 0.06
Cumulative prednisone dose (mg) 4,992 6 422 8,905 6 700 13,382 6 891 16,984 6 1,117
Current prednisone dose (mg/d) 17.60 6 0.61 9.37 6 1.01 6.80 6 0.87 5.72 6 0.99
Cyclosporine level (ng/mL) 239 6 14 193 6 9 150 6 12 129 6 11
Rejection episodes 17/45 (38)
Major infections 14/45 (31)
Days in intensive care unit 7.14 6 0.61
In-hospital days 25.41 6 2.63 50.90 6 5.17
Group C
No. of patients 47 40 31 26
Creatinine (mg/dL) 1.29 6 0.11 1.36 6 0.14 1.35 6 0.08 1.35 6 0.06
Cumulative prednisone dose (mg) 4,827 6 338 8,338 6 517 11,993 6 594 15,048 6 612
Current prednisone dose (mg/d) 17.87 6 0.58 8.94 6 0.90 6.08 6 0.58 4.61 6 0.53
Cyclosporine level (ng/mL) 251 6 16 190 6 12 153 6 11 135 6 10
Rejection episodes 16/54 (30)
Major infections 15/54 (28)
Days in intensive care unit 6.78 6 0.61
In-hospital days 28.72 6 2.84 50.90 6 5.57
NOTE. Group A, DM with pharmacological treatment; group B, DM without pharmacological treatment; group C, no DM. Values
expressed as mean 6 SEM or number of patients/total number (percent). All comparisons are between groups and not significant.
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lestasis, as noted), incidence of hepatocellular carci-
noma, and liver and renal function.
The most important finding of this report is the
confirmation of the lack of an adverse outcome in liver
transplant recipients with DM compared with patients
without DM. Post-OLT survival of liver transplant re-
cipients with DM had been reported to be less than the
survival of those without DM in 1 series,13 but the rest
of the series reported to date did not find significant
differences.12,14-17 Our patients with DM had greater
survival and it was even greater in those who required
pharmacological treatment to achieve metabolic con-
trol. Excluding the incidence of post-OLT DM, the rest
of the outcomes studied were not different among
groups. We studied the incidence of rejection, major
infections, and such metabolic complications as obesity
and hyperlipidemia. In addition, graft (expressed as se-
rum albumin levels and prothrombin time) and renal
function (expressed as creatinine levels) were similar
among groups. Most previous studies had found a sim-
ilar incidence of complications in both groups. Only
Trail et al14 found a greater incidence of minor bacterial
and fungal infections in patients with DM. These in-
vestigators also found that patients with pre-OLT DM
had worse renal function in the first post-OLT year
than patients without DM. In the same way, patients
with and without post-OLT DM in our series had
similar post-OLT evolutions. The good evolution of
patients with pre-OLT DM after OLT must be inter-
preted cautiously because none of our patients had se-
vere organ damage caused by pre-OLT DM.
The most important difference in the evolution of
Table 3. Post-OLT Incidence of DM, Obesity, Hypercholesterolemia, Hypertriglyceridemia, and Arterial Hypertension
3 Months 1 Year 2 Years 3 Years
Group A
No. of patients 16 14 11 7
DM 14/16 (87)*,† 12/14 (86)*,† 9/11 (82)*,† 4/7 (57)*,†
BMI
Normal 9/15 (60) 3/13 (23) 2/10 (20) 0/6 (0)
Overweight 3/15 (20) 6/13 (46) 4/10 (40) 3/6 (50)
Obese 3/15 (20) 4/13 (31) 4/10 (40) 3/6 (50)
Hypercholesterolemia 6/16 (37) 3/14 (21) 4/11 (36) 2/7 (29)
Hypertriglyceridemia 3/16 (19) 6/14 (43) 6/11 (55) 3/7 (43)
Arterial hypertension 9/16 (56) 10/14 (71) 10/11 (91) 4/7 (57)
Group B
No. of patients 44 38 29 23
DM 16/44 (36)* 9/38 (24) 3/29 (10) 2/23 (9)
BMI
Normal 32/43 (74) 19/38 (50) 13/29 (45) 9/21 (43)
Overweight 7/43 (16) 8/38 (21) 5/29 (17) 2/21 (10)
Obese 4/43 (9) 11/38 (29) 11/29 (38) 10/21 (48)
Hypercholesterolemia 14/43 (33) 14/38 (37) 7/29 (24) 7/23 (30)
Hypertriglyceridemia 8/40 (20) 13/38 (34) 4/29 (14) 4/23 (17)
Arterial hypertension 27/44 (61) 25/38 (66) 21/29 (72) 18/23 (78)
Group C
No. of patients 47 40 31 26
DM 1/47 (2) 3/40 (7) 1/31 (3) 1/26 (4)
BMI
Normal 29/47 (62) 13/38 (34) 10/30 (33) 9/26 (35)
Overweight 8/47 (17) 10/38 (26) 8/30 (27) 7/26 (27)
Obese 10/47 (21) 15/38 (39) 12/30 (40) 10/26 (38)
Hypercholesterolemia 12/47 (26) 15/40 (37) 10/31 (32) 9/25 (36)
Hypertriglyceridemia 12/40 (30) 10/40 (25) 9/30 (30) 6/25 (24)
Arterial hypertension 20/47 (43) 30/40 (75) 24/31 (77) 21/26 (81)
NOTE. Group A, DM with pharmacological treatment; group B, DM without pharmacological treatment; group C, no DM. Values
expressed as number of patients/total number (percent).
* P , .005 versus group C.
† P , .02 versus group B.
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patients with and without pre-OLT DM is the inci-
dence of post-OLT DM. Most patients who required
pharmacological treatment before OLT to achieve
blood glucose control required treatment in the next
years. Patients with pre-OLT DM not requiring treat-
ment also had a greater incidence of post-OLT DM
during the first year, but the difference between these
patients and those without DM lost its significance
later. Post-OLT DM was very infrequent in patients
without DM before OLT, and none of the patients with
normal OGTT results had post-OLT DM at any of the
times studied (3, 12, 24, and 36 months). As shown, the
incidence of post-OLT DM is greatest in the early post-
OLT period, probably because of the greater doses of
immunosuppressive drugs used during this period and
the persistence of some degree of portasystemic shunt-
ing. None of the patients without DM at the end of the
first year became diabetic later.
In their report, Navasa et al12 found that the only
factor predicting the development of post-OLT DM
among patients without DM was rejection because the
number of rejection episodes was greater in patients
with than without post-OLT DM. In our series, the
incidence of rejection in patients with and without
post-OLT DM was similar, as were the rest of the
variables studied. The only difference between both
groups was the greater incidence of pre-OLT DM re-
quiring treatment in patients who remain diabetics.
There was also a clear trend to a greater incidence of
DM 1 year after OLT in those patients who had pre-




(n 5 24) P
Pre-OLT
Age (yr) 53.2 6 9.8 55.7 6 7.1 NS
Sex NS
Men 49 (72) 20 (83)
Women 19 (28) 4 (17)
DM ,.001
No 37 (54) 3 (12)
Without treatment 29 (43) 9 (38)
With treatment 2 (3) 12 (50)
Weight NS
Normal 38 (56) 13 (54)
Overweight 17 (25) 8 (33)
Obese 13 (19) 3 (13)
Child-Pugh stage NS
A 10 (15) 3 (12)
B 35 (51) 11 (46)
C 23 (34) 10 (42)
Hepatocellular carcinoma 16 (24) 9 (37) .146
Hypercholesterolemia 5 (7) 1 (4) NS
Arterial hypertension 5 (7) 3 (12) NS
Post-OLT
Weight NS
Normal 28 (42) 7 (32)
Overweight 15 (22) 9 (41)
Obese 24 (36) 6 (27)
Immunosuppression NS
Cyclosporine A 60 (88) 22 (92)
Tacrolimus 8 (12) 2 (8)
Cyclosporine level (ng/mL) 194 6 9 180 6 11 NS
Cumulative prednisone (mg) 8,382 6 477 8,575 6 623 NS
Prednisone (mg/d) 8.87 6 0.75 8.33 6 0.95 NS
NOTE. Data expressed as mean 6 SEM or number (%).
Abbreviation: NS, not significant.
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OLT DM not requiring treatment. Similarly, Bigam et
al17 found that 1 of the predisposing factors for post-
OLT DM is pre-OLT DM. Contrary to our findings,
these investigators also found hepatitis C–related liver
failure and male sex as independent predictors of DM 1
year after OLT.
A recent report from Italy may help explain these find-
ings.8 In their study, Perseghin et al found that patients
with cirrhosis with DM may have insulin resistance and
reduced b-cell function. The first of these 2 alterations is
reversed after OLT, but reduced b-cell secretion is not.
This reduced b-cell function probably has a key role in the
maintenance of DM after OLT, making the development
of DM almost exclusive of patients who have decreased
insulin secretion before OLT.
In conclusion, patients with end-stage liver cirrhosis
have a high prevalence of DM. This condition does not
have an adverse consequence on morbidity and mortal-
ity other than the maintenance of their diabetic state.
The only risk factor for the development of post-OLT
DM is pre-OLT DM, but this complication does not
have an adverse effect on midterm survival.
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Table 5. Comparison of the Evolution After OLT in
Patients With and Without DM 1 Year After OLT
No
Post-OLT
DM (n 5 68)
Post-OLT
DM
(n 5 24) P
Weight NS
Normal (%) 28 (42) 7 (32)
Overweight (%) 15 (22) 9 (41)
Obese (%) 24 (36) 6 (27)
Arterial hypertension
(%) 47 (69) 18 (75) NS
Hypercholesterolemia
(%) 24 (35) 8 (33) NS
Hypertriglyceridemia
(%) 19 (28) 10 (42) NS
Rejection (%) 22 (32) 9 (37) NS
Major infection (%) 17 (25) 4 (17) NS
Hospitalization (d)
ICU 7.01 6 0.50 6.54 6 0.57 NS
Until discharge 27.32 6 2.44 25.25 6 2.92 NS
1 Year (cumulative) 46.81 6 3.79 52.88 6 6.75 NS
Albumin (g/dL) 3.88 6 0.05 3.79 6 0.08 NS
Creatinine (mg/dL) 1.30 6 0.09 1.22 6 0.06 NS
Prothrombin rate (%) 93 6 2 96 6 3 NS
NOTE. Data expressed as mean 6 SEM or number (per-
cent).
Abbreviations: ICU, intensive care unit; NS, not significant.
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